Published in:
Open Access
01-12-2016 | Letter
Prognosis of extremely severe lactic acidosis in metformin-treated patients with septic shock: continuous (?) renal replacement therapy in the spotlight!
Authors:
Patrick M. Honore, Herbert D. Spapen
Published in:
Critical Care
|
Issue 1/2016
Login to get access
Excerpt
We read with interest the recent paper by Doenyas-Barak et al. [
1] comparing the prognosis of extremely elevated plasma lactate levels between metformin (MET)-treated and MET-naive patients with septic shock. The most remarkable finding was a highly significant lower in-hospital mortality (56.8 vs. 88.1 %,
p < 0.0001) in MET users despite a more explicit risk profile (diabetes, older age) and greater baseline disease severity (higher incidences of cardiovascular disease, acute kidney injury, and underlying malignancy) [
1]. The authors briefly elaborate on this unexpected survival benefit by pointing out some potential protective MET-related anti-inflammatory, anti-thrombotic, and cellular effects. However, we believe that the observed difference in mortality rate is most likely due to the more frequent use of renal replacement therapy (RRT) in the MET-treated population (38.6 vs. 21.2 %,
p = 0.13). …